In last trading session, Autolus Therapeutics plc ADR (NASDAQ:AUTL) saw 1.33 million shares changing hands with its beta currently measuring 1.78. Company’s recent per share price level of $2.31 trading at -$0.01 or -0.43% at ring of the bell on the day assigns it a market valuation of $614.78M. That closing price of AUTL’s stock is at a discount of -116.45% from its 52-week high price of $5.00 and is indicating a premium of 51.95% from its 52-week low price of $1.11. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.03 million shares which gives us an average trading volume of 2.30 million if we extend that period to 3-months.
For Autolus Therapeutics plc ADR (AUTL), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Autolus Therapeutics plc ADR (NASDAQ:AUTL) trade information
Upright in the red during last session for losing -0.43%, in the last five days AUTL remained trading in the green while hitting it’s week-highest on Thursday, 06/26/25 when the stock touched $2.31 price level, adding 1.28% to its value on the day. Autolus Therapeutics plc ADR’s shares saw a change of -37.90% in year-to-date performance and have moved 12.14% in past 5-day. Autolus Therapeutics plc ADR (NASDAQ:AUTL) showed a performance of 47.13% in past 30-days. Number of shares sold short was 12.71 million shares which calculate 5.19 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 8 to the stock, which implies a rise of 71.12% to its current value. Analysts have been projecting 7.6 as a low price target for the stock while placing it at a high target of 11. It follows that stock’s current price would drop -229.0% in reaching the projected high whereas dropping to the targeted low would mean a loss of -229.0% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 21.36% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -4.39% while estimates for its earnings growth in next 5 years are of 19.72%.
Autolus Therapeutics plc ADR (NASDAQ:AUTL)’s Major holders
Insiders are in possession of 18.09% of company’s total shares while institution are holding 86.01 percent of that, with stock having share float percentage of 105.00%. Investors also watch the number of corporate investors in a company very closely, which is 86.01% institutions for Autolus Therapeutics plc ADR that are currently holding shares of the company. SYNCONA PORTFOLIO LTD is the top institutional holder at AUTL for having 21.35 million shares of worth $74.29 million. And as of 2024-06-30, it was holding 8.0243 of the company’s outstanding shares.
The second largest institutional holder is BLACKSTONE INC., which was holding about 20.49 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.7006 of outstanding shares, having a total worth of $71.29 million.
